Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback